Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1161/JAHA.120.017529 http://scihub22266oqcxt.onion/10.1161/JAHA.120.017529 32515253!7660727!32515253     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Am+Heart+Assoc 2020 ; 9 (14): e017529 Nephropedia Template TP {{tp|p=32515253|t=2020. Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019 |pdf=|usr=}}{{32515253}} gab.com Text Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019 JO: J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=32515253 #FOAvip Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID-19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID-19 treatments. Common unintended nontherapeutic target effects of COVID-19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P-glycoprotein inhibition. Drug-drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID-19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID-19 patients with concomitant atrial fibrillation. Twit Text FOAVip Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019 ????J Am Heart Assoc http://www.kidney.de/pget.php?&tw=1&pmid=32515253 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32515253 #FOAvip English Wikipedia <ref>{{Cite pmid|32515253}}</ref> Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019 #MMPMID32515253 Rattanawong P; Shen W; El Masry H; Sorajja D; Srivathsan K; Valverde A; Scott LR J Am Heart Assoc 2020[Jul]; 9 (14): e017529 PMID32515253show ga Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID-19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID-19 treatments. Common unintended nontherapeutic target effects of COVID-19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P-glycoprotein inhibition. Drug-drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID-19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID-19 patients with concomitant atrial fibrillation. |Anti-Arrhythmia Agents/adverse effects/pharmacokinetics/*therapeutic use[MESH] |Anticoagulants/adverse effects/pharmacokinetics/*therapeutic use[MESH] |Antiviral Agents/adverse effects/pharmacokinetics/*therapeutic use[MESH] |Atrial Fibrillation/diagnosis/epidemiology/*therapy[MESH] |Betacoronavirus/*pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/diagnosis/*drug therapy/epidemiology/virology[MESH] |Drug Interactions[MESH] |Host Microbial Interactions[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/epidemiology/virology[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Guidance on Short-Term Management of Atrial Fibrillation in Coronaviru(epmc).pdf DeepDyve Pubget Overpricing